Reporter and Curator: Dr. Sudipta Saha, Ph.D.
The metabolite pool of cells and tissues represents the end result of metabolism determined by genetic, environmental and nutritional factors. The metabolic profile of biological systems is closely related to the individual phenotype and reflects the biological endpoint of a multitude of pathways and their interaction with any confounding stimuli. Cancer cells exhibit activation of specific metabolic pathways to compensate for their extremely high energy demands. Indeed increased glucose uptake and lactate production and decreased respiration are key phenomena of tumour cell metabolism. In particular, the generation of an acidic microenvironment through increased lactate production, even under aerobic conditions, may confer extracellular matrix degeneration and exert toxic effects on surrounding cell populations, while being harmless for the cancer cell itself. Thus, the metabolic adaptations may indeed be critical for the development of accelerated proliferation and the invasive growth of tumour cell populations. The molecular mechanisms underlying the metabolic hallmarks of cancer are still poorly understood, although genetic, epigenetic and environmental factors driving cancer development and progression will interact to determine the metabolic phenotype of tumour cells. Recent studies suggest that metabolic changes play a pivotal role in the biology of renal cell carcinoma – a tumour entity that is largely resistant to conventional chemo- and radiotherapy. The metabolic profile of renal tumours may thus serve as a reliable biomarker of malignant transformation and biological behaviour.
Recent advances in metabolic profiling technologies by providing quantitative measures of metabolite profiles from gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) based technology present the opportunity to apply this technique in human specimens. Global metabolic profiling has emerged as a promising approach to characterize the metabolite pool within a cell, tissue or bodily fluid under certain conditions, such as health or disease status. Metabolic profiling is applied to monitor the health to disease continuum and has the potential of increasing our understanding of the mechanisms of disease. Thus the characterization of the metabolic features in tumours is expected to provide a better understanding of the mechanisms of malignant transformation and progression and may lead to the identification of metabolic biomarkers for cancer detection and prognostication. However, comparative profiling of low molecular weight compounds, such as sugars, lipids and amino acids, in cancer as compared to the corresponding normal tissue is a rather unexplored area. The objective of this study was to characterize the key metabolic features of renal cell carcinoma using GC-TOF-MS and mutual information as well as decision tree-based data analysis.
Hypoxia is key in tumour cell behaviour. Hypoxia, via hypoxia inducible factor, plays a key role in the metabolic changes in the kidney cancer cell and influences different pathways. Pathways that use tyrosine kinases and mammalian target of rapamycin are well studied. Hypoxia-related effects on vascular epithelial growth factors and angiogenesis will influence the metabolic status of the cell significantly. This is the basis of inhibitor-type drugs or antibody blocking agents and the effect on the clinical course of renal cell carcinoma patients. Detailed information about metabolic changes is crucial to understanding these mechanisms more clearly. Treating renal cell carcinoma patients is not like treating one disease. Renal cell carcinoma has different morphologic entities with distinct differences in cytogenetic background. These differences should be reflected in the different approaches of diagnostic and therapeutic strategies. This consideration will help to increase the efficacy of novel agents and decrease unnecessary side-effects. Metabolomics explains the importance of explaining genetic changes and the functional outcome of the tumour cells. In addition, epidemiologic differences in incidence and prevalence in different parts of the world may help provide insight into the etiology of kidney cancer. Factors that may influence renal cancer likelihood (eg, obesity, antihypertensive therapy) may have an explanation in metabolomics.
Source References:
http://www.europeanurology.com/article/S0302-2838(12)01352-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/19845817
http://www.ncbi.nlm.nih.gov/pubmed/18072195
http://www.ncbi.nlm.nih.gov/pubmed/17123452
http://www.ncbi.nlm.nih.gov/pubmed/20464042
2012pharmaceutical
Aashir Awan, Phd
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
amnondanzig1724
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
evelinacohn
Gail S Thornton
Irina Robu
jdpmd
kellyperlman
Ed Kislauskis
larryhbern
lmulligan13gmailcom
marzankhan
megbaker58
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
can you expand on this..
glucose uptake and lactate production and decreased respiration are key phenomena of tumour cell metabolism. In particular, the generation of an acidic microenvironment through increased lactate production, even under aerobic conditions, may confer extracellular matrix degeneration and exert toxic effects on surrounding cell populations,
Renal cell carcinoma is somewhat a misnomer…
The renal cortex is highly vascular, and it relies on aerobic mitochondrial metabolism. The renal medulla is essentially anaerobic, and it is prone to vascular necrosis. If you review the structure of the nephron you see the role of the medullary descending and ascending loops of Henle providing a concentration gradient for electrolyte retention.
In renal cell carcinoma, which kidney epithelium are we looking at? The lactic acid production is readily released into the circulation in the cortex, and the heart uses lactic acid as fuel. Why is there lactic acid production? The reversion to aerobic glycolysis, which produces 2 ATP from two 3-carbon sugars, whereas, the TCA cycle produces 18 ATP. The high energy P is the energy of life. But the diversion, linked to the fumarate to malate conversion, would block this highly energetic process. The TCA cycle is now tied up in synthetic activity, rather than anabolism. Where does the energy come to support the rest of the organism? This is an active driven process of autocannabolization requiring breakdown of lean body mass to provide gluconeogenic precursors from amino acids released. It is essentially related to the events driving sepsis – under the control of TNF-a, and driven by hypercortisolemia, insulin resistance, and reprioritizing hepartic protein synthesis – which leads to decreased production of transthyretin, transcortin, and retinoid-binding protein. The binding equilibrium would result in an adaptive hyperthyroid, hyperretinoid, and hyperactive corticoid state based on the availability of the free ligand.
What might one expect from metabolomics studies?
Dr. Saha
Thank you for this article. The references are fine, you or Dr. Larry will need to go back to the references and RE-WRITE an article on the subject matter of the Title to this article for the Metabolomics e-Book.
This article at present format, does not qualify for the e-Book. It is a mere place holder in the Journal.
Please comment on my evaluation